Keros CSO automatic tax sale of 3,873 shares

Keros Therapeutics Chief Science Officer Lorena Raquel Lerner reported an automatic sale of 3,873 shares of common stock on February 18, 2026.

Rhea-AI Filing Summary

Keros Therapeutics Chief Science Officer Lorena Raquel Lerner reported an automatic sale of 3,873 shares of common stock on February 18, 2026. The issuer has a “sell-to-cover” policy, so these shares were sold solely to cover tax withholding on vesting restricted stock units.

The open-market sale occurred at a weighted average price of $16.35 per share, with individual trades ranging from $16.05 to $16.65. After this tax-related transaction, Lerner directly held 31,127 shares of Keros Therapeutics common stock.

Insider Trade Summary

Net Seller: 3,873 shares

Net Sell 1 txn

Insider Lerner Lorena Raquel

Role Chief Science Officer

Sold 3,873 shs ($63K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,873	$16.35	$63K

Holdings After Transaction: Common Stock — 31,127 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Keros Therapeutics (KROS) report for Lorena Raquel Lerner?

Keros Therapeutics reported that Chief Science Officer Lorena Raquel Lerner sold 3,873 shares of common stock. The sale occurred on February 18, 2026, and was tied to tax withholding obligations related to the vesting of restricted stock units under the company’s sell-to-cover policy.

Was the KROS insider sale by Lorena Lerner a discretionary transaction?

No, the sale was not discretionary. The company’s sell-to-cover policy required selling 3,873 shares to satisfy tax withholding obligations when Lerner’s restricted stock units vested. The footnote states these sales were automatic and not made at the reporting person’s discretion.

At what prices were the 3,873 Keros Therapeutics shares sold on February 18, 2026?

The 3,873 shares were sold at a weighted average price of $16.35 per share. Individual trades took place in a range from $16.05 to $16.65, and the filing notes that detailed trade information is available upon request from the issuer or the SEC staff.

How many Keros Therapeutics (KROS) shares does Lorena Lerner hold after this Form 4 transaction?

After the tax-related sale, Lorena Raquel Lerner directly holds 31,127 shares of Keros Therapeutics common stock. This post-transaction holding figure reflects her remaining direct ownership following the automatic sale of 3,873 shares to cover tax withholding tied to restricted stock unit vesting.

What role does Lorena Raquel Lerner hold at Keros Therapeutics (KROS)?

Lorena Raquel Lerner serves as Chief Science Officer at Keros Therapeutics. As an executive officer, her equity transactions, including the automatic sell-to-cover sale of 3,873 shares reported on this Form 4, must be disclosed to provide transparency about her ownership in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lerner Lorena Raquel

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/18/2026		S		3,873(1)	D	$16.35(2)	31,127	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.65 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Esther Cho, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.